Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A Look into the Future of Chronic Pain Management

An Interview with Innocan Pharma’s CEO, Iris Bincovich. Innocan Pharma is gaining attention for its innovative pain relief solutions — particularly through its slow-release injection technology. This cutting-edge approach delivers synthetic Cannabidi...

NervGen Pharma: Proof that NVG-291 works?

It’s arguably a Eureka moment for investors in NervGen Pharma (TSX.V: NGEN) (OTCQB: NGENF). Tantalizing anecdotal “evidence” has just been published that suggests that NervGen’s prospective wonder-drug — NVG-29...

BoC’s Double Rate Cut: Is it a benefit for Canadians

The Bank of Canada (BoC) has implemented a 50-basis-point interest rate cut. This is in responds to a weakening labor market and a 5-year bond yield drop to 2.8%. With unemployment at 6.8%—its highest since 2017 (excluding pandemic years)—the move aims to stimulate the ec...

From now on, dynaCERT instead of Bitcoin or NVIDIA?

While Bitcoin and NVIDIA dominate the headlines and investors hope for the next rally, a promising opportunity is emerging with dynaCERT Inc. (ISIN: CA26780A1084 | Ticker-TSX: DYA) for those seeking a true growth story. Read on to learn why this Canadian company may now b...

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...

Buzz on the Bullboards: From innovating traffic enforcement to cancer breakthroughs

The past week on the TSX has been one for the books, with significant gains driven largely by advancements in the technology sector. The S&P 500 and NASDAQ have hit fresh highs, a clear sign of a hungry market bolstered by technology stocks. This momentum has put a spot...

Bitcoin company adds convenience of modern banking

The following is a transcription of the above video, and The Market Online has edited it for clarity . Bitcoin Well Inc. (TSXV:BTCW) is a non-custodial fintech company, with a primary focus on empowering people to interact directly with the Bitcoin protocol. J...

Buzz on the Bullboards: 3 stocks breaking the silence of a quiet June

“Sell in May and go away” is a theme investors and stock traders know well, and during this quieter month of June ahead of summer, some public Canadian companies have been engaging in serious business. This week, we saw the TSX hit a one-month ...

Buzz on the Bullboards: Looking for volatility-proof stocks?

This week, investors witnessed significant developments in Canadian and U.S. markets, with attention drawn to the pivotal decisions made by central banks and notable movements in key sectors. Let’s get into the highlights of the past week’s...

Buzz on the Bullboards: Where volatility meets opportunity

It has been a wild ride for markets on Bay Street and Wall Street this week. Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day. It is reporting season for many companies, and Stockhouse users seem...
1 2 3 4 5 6 7 8 9 10